12. Nagasue N, Uchida M, Makino Y, Takemoto Y, Yamanoi A, Hayashi T, Chang YC, Kohno H, Nakamura T, Yukaya H: Incidence and factors associated with intrahepatic recurrence following resection of hepatocellular carcinoma. Gastroenterology 1993, 105:488-494.
13. Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, Sugawara Y, Minagawa M, Takayama T, Kawasaki S, Makuuchi M: Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003, 38:200-207.
14. Benvegnu L, Noventa F, Bernardinello E, Pontisso P, Gatta A, Alberti A:
Evidence for an association between the aetiology of cirrhosis and pattern of hepatocellular carcinoma development. Gut 2001, 48:110-115.
15. Benvegnu L, Alberti A: Patterns of hepatocellular carcinoma development in hepatitis B virus and hepatitis C virus related cirrhosis. Antiviral Res 2001, 52:199-207.
16. Pompili M, Rapaccini GL, Covino M, Pignataro G, Caturelli E, Siena DA, Villani MR, Cedrone A, Gasbarrini G: Prognostic factors for survival in patients with compensated cirrhosis and small hepatocellular carcinoma after percutaneous ethanol injection therapy. Cancer 2001, 92:126-135.
17. Chen PJ, Chen DS, Lai MY, Chang MH, Huang GT, Yang PM, Sheu JC, Lee SC, Hsu HC, Sung JL: Clonal origin of recurrent hepatocellular
carcinomas. Gastroenterology 1989, 96:527-529.
18. Kumada T, Nakano S, Takeda I, Sugiyama K, Osada T, Kiriyama S, Sone Y, Toyoda H, Shimada S, Takahashi M, Sassa T: Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma.
Hepatology 1997, 25:87-92.
19. Nishizaki T, Takenaka K, Yanaga K, Soejima Y, Uchiyama H, Kishikawa K, Sugimachi K: Early detection of recurrent hepatocellular carcinoma.
Hepatogastroenterology 1997, 44:508-513.
20. Shibata T, Kubo S, Itoh K, Sagoh T, Nishimura K, Nakano Y, Yamaoka Y, Ozawa K, Konishi J: Recurrent hepatocellular carcinoma: usefulness of ultrasonography compared with computed tomography and AFP assay. J
Clin Ultrasound 1991, 19:463-469.
21. Aoyagi Y, Oguro M, Yanagi M, Mita Y, Suda T, Suzuki Y, Hata K, Ichii K, Asakura H: Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma. Cancer 1996, 77:1781-1786.
22. Shirabe K, Takenaka K, Gion T, Shimada M, Fujiwara Y, Sugimachi K:
Significance of alpha-fetoprotein levels for detection of early recurrence of hepatocellular carcinoma after hepatic resection. J Surg Oncol 1997, 64:143-146.
23. Shimada M, Takenaka K, Gion T, Fujiwara Y, Kajiyama K, Maeda T, Shirabe K, Nishizaki T, Yanaga K, Sugimachi K: Prognosis of recurrent
hepatocellular carcinoma: a 10-year surgical experience in Japan.
Gastroenterology 1996, 111:720-726.
24. Bruix J, Sherman M: Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236.
25. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC: Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm. Gastroenterology 2004, 127:1714-1723.
26. Shiina S, Teratani T, Obi S, Sato S, Tateishi R, Fujishima T, Ishikawa T, Koike Y, Yoshida H, Kawabe T, Omata M: A randomized controlled trial of
radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005, 129:122-130.
27. Livraghi T, Lazzaroni S, Meloni F, Solbiati L: Risk of tumour seeding after percutaneous radiofrequency ablation for hepatocellular carcinoma. Br J
Surg 2005, 92:856-858.
28. Schotman SN, De Man RA, Stoker J, Zondervan PE, Ijzermans JN:
Subcutaneous seeding of hepatocellular carcinoma after percutaneous needle biopsy. Gut 1999, 45:626-627.
29. Tateishi R, Shiina S, Teratani T, Obi S, Sato S, Koike Y, Fujishima T, Yoshida H, Kawabe T, Omata M: Percutaneous radiofrequency ablation for
hepatocellular carcinoma. An analysis of 1000 cases. Cancer 2005, 103:1201-1209.
30. Yuen MF, Cheng CC, Lauder IJ, Lam SK, Ooi CG, Lai CL: Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 2000, 31:330-335.
31. Wilson JM, Jungner YG: [Principles and practice of mass screening for disease]. Bol Oficina Sanit Panam 1968, 65:281-393.
32. Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G, Piscaglia F, Gramantieri L, Zanetti M, Sherman M: Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001, 48:251-259.
33. Tanaka S, Kitamura T, Nakanishi K, Okuda S, Yamazaki H, Hiyama T, Fujimoto I: Effectiveness of periodic checkup by ultrasonography for the
early diagnosis of hepatocellular carcinoma. Cancer 1990, 66:2210-2214.
34. Zoli M, Magalotti D, Bianchi G, Gueli C, Marchesini G, Pisi E: Efficacy of a surveillance program for early detection of hepatocellular carcinoma.
Cancer 1996, 78:977-985.
35. Cottone M, Turri M, Caltagirone M, Parisi P, Orlando A, Fiorentino G, Virdone R, Fusco G, Grasso R, Simonetti RG, et al.: Screening for
hepatocellular carcinoma in patients with Child's A cirrhosis: an 8-year prospective study by ultrasound and alphafetoprotein. J Hepatol 1994, 21:1029-1034.
36. Cottone M, Turri M, Caltagirone M, Maringhini A, Sciarrino E, Virdone R, Fusco G, Orlando A, Marino L, Pagliaro L: Early detection of hepatocellular carcinoma associated with cirrhosis by ultrasound and alfafetoprotein: a prospective study. Hepatogastroenterology 1988, 35:101-103.
37. Tremolda F, Benevegnu L, Drago C, Casarin C, Cechetto A, Realdi G, Ruol A:
Early detection of hepatocellular carcinoma in patients with cirrhosis by alphafetoprotein, ultrasound and fine-needle biopsy.
Hepatogastroenterology 1989, 36:519-521.
38. Sherman M, Peltekian KM, Lee C: Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population.
Hepatology 1995, 22:432-438.
39. Pateron D, Ganne N, Trinchet JC, Aurousseau MH, Mal F, Meicler C, Coderc E, Reboullet P, Beaugrand M: Prospective study of screening for
hepatocellular carcinoma in Caucasian patients with cirrhosis. J Hepatol 1994, 20:65-71.
40. Larcos G, Sorokopud H, Berry G, Farrell GC: Sonographic screening for hepatocellular carcinoma in patients with chronic hepatitis or cirrhosis:
an evaluation. AJR Am J Roentgenol 1998, 171:433-435.
41. Chen DS, Sung JL, Sheu JC, Lai MY, How SW, Hsu HC, Lee CS, Wei TC:
Serum alpha-fetoprotein in the early stage of human hepatocellular carcinoma. Gastroenterology 1984, 86:1404-1409.
42. Sheu JC, Sung JL, Chen DS, Yang PM, Lai MY, Lee CS, Hsu HC, Chuang CN, Yang PC, Wang TH, et al.: Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology 1985, 89:259-266.
43. Fung KT, Li FT, Raimondo ML, Maudgil D, Mancuso A, Tibballs JM, Watkinson AA, Patch D, Burroughs AK: Systematic review of radiological imaging for hepatocellular carcinoma in cirrhotic patients. Br J Radiol 2004, 77:633-640.
44. Marrero JA, Lok AS: Newer markers for hepatocellular carcinoma.
Gastroenterology 2004, 127:S113-119.
45. Benowitz S: Liver cancer biomarkers struggling to succeed. J Natl Cancer
Inst 2007, 99:590-591.
46. Kanmura S, Uto H, Kusumoto K, Ishida Y, Hasuike S, Nagata K, Hayashi K, Ido A, Stuver SO, Tsubouchi H: Early diagnostic potential for
hepatocellular carcinoma using the SELDI ProteinChip system.
Hepatology 2007, 45:948-956.
47. Gitlin D, Perricelli A, Gitlin GM: Synthesis of -fetoprotein by liver, yolk sac, and gastrointestinal tract of the human conceptus. Cancer Res 1972, 32:979-982.
48. Abelev GI, Perova SD, Khramkova NI, Postnikova ZA, Irlin IS: Production of embryonal α-globulin by transplantable mouse hepatomas.
Transplantation 1963, 1:174-180.
49. IuS T: [Detection of Embryo-Specific Alpha-Globulin in the Blood Serum of a Patient with Primary Liver Cancer.]. Vopr Med Khim 1964, 10:90-91.
50. Zaman SN, Melia WM, Johnson RD, Portmann BC, Johnson PJ, Williams R:
Risk factors in development of hepatocellular carcinoma in cirrhosis:
prospective study of 613 patients. Lancet 1985, 1:1357-1360.
51. Lok AS, Lai CL: alpha-Fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: role in the early detection of
hepatocellular carcinoma. Hepatology 1989, 9:110-115.
52. Oka H, Tamori A, Kuroki T, Kobayashi K, Yamamoto S: Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology 1994, 19:61-66.
53. Trevisani F, D'Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni P, Domenicali M, De Notariis S, Roda E, Bernardi M: Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J
Hepatol 2001, 34:570-575.
54. Johnson PJ: The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis 2001, 5:145-159.
55. 廖運範: 慢性
B
型肝炎病毒感染 于 肝炎肝硬化與肝癌初版 edn. 台北
市: 橘井文化; 2006.56. Liaw YF, Tai DI, Chen TJ, Chu CM, Huang MJ: Alpha-fetoprotein changes in the course of chronic hepatitis: relation to bridging hepatic necrosis and hepatocellular carcinoma. Liver 1986, 6:133-137.
57. Chen DS, Sung JL: Serum alphafetoprotein in hepatocellular carcinoma.
Cancer 1977, 40:779-783.
58. Sung JL, Liaw YF, Lin WS, Chen TH: Alpha-fetoprotein in liver diseases in Taiwan. Taiwan Yi Xue Hui Za Zhi 1974, 73:178-183.
59. Lin TY, Chu SH, Chen MF, Chen CH: Serum alpha-fetoglobulin and primary cancer of the liver in Taiwan. Cancer 1972, 30:435-443.
60. Wu JC, Lee SD, Hsiao KJ, Wang SS, Chou P, Tsao D, Tsai YT, Lui WY, Chiang JH, Lo KJ: Mass screening of primary hepatocellular carcinoma by alpha-fetoprotein in a rural area of Taiwan--a dried blood spot method.
Liver 1988, 8:100-104.
61. Sherman M: Alphafetoprotein: an obituary. J Hepatol 2001, 34:603-605.
62. McMahon BJ, Alberts SR, Wainwright RB, Bulkow L, Lanier AP: Hepatitis B-related sequelae. Prospective study in 1400 hepatitis B surface
antigen-positive Alaska native carriers. Arch Intern Med 1990, 150:1051-1054.
63. McMahon BJ, Bulkow L, Harpster A, Snowball M, Lanier A, Sacco F, Dunaway E, Williams J: Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology 2000, 32:842-846.
64. Gupta S, Bent S, Kohlwes J: Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann Intern Med 2003, 139:46-50.
65. Farinati F, Marino D, De Giorgio M, Baldan A, Cantarini M, Cursaro C, Rapaccini G, Del Poggio P, Di Nolfo MA, Benvegnu L, et al: Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol 2006, 101:524-532.
66. Chu ML, Lin WS, Yoshida TO, Chu SH, Lin TY: Demonstration of
alpha-Fetoglobulin in hepatoma tissue by fluorescent antibody technique.
Cancer 1974, 34:268-273.
67. Volk ML, Hernandez JC, Su GL, Lok AS, Marrero JA: Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3. Cancer Biomark 2007, 3:79-87.
68. Li D, Mallory T, Satomura S: AFP-L3: a new generation of tumor marker for hepatocellular carcinoma. Clin Chim Acta 2001, 313:15-19.
69. Fujioka M, Nakashima Y, Nakashima O, Kojiro M: Immunohistologic study on the expressions of alpha-fetoprotein and protein induced by vitamin K absence or antagonist II in surgically resected small hepatocellular carcinoma. Hepatology 2001, 34:1128-1134.
70. Yuen MF, Lai CL: Serological markers of liver cancer. Best Pract Res Clin
Gastroenterol 2005, 19:91-99.
71. Liebman HA: Isolation and characterization of a hepatoma-associated abnormal (des-gamma-carboxy)prothrombin. Cancer Res 1989, 49:6493-6497.
72. Fujiyama S, Tanaka M, Maeda S, Ashihara H, Hirata R, Tomita K: Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma. Oncology 2002, 62 Suppl 1:57-63.
73. Lamerz R, Hayes P, Hoffmann R-T, Löhe F, Shiratori Y, Taketa K: National Academy of Clinical Biochemistry Guidelines for the Use of Tumor Markers in Primary Liver Cancer.
http://wwwaaccorg/NR/rdonlyres/491D2679-1801-4075-9B59-3106B4A42629 /0/chp3d_liverpdf 2006.
74. Liebman HA, Furie BC, Tong MJ, Blanchard RA, Lo KJ, Lee SD, Coleman MS, Furie B: Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med 1984, 310:1427-1431.
75. Tanabe Y, Ohnishi K, Nomura F, Iida S: Plasma abnormal prothrombin levels in patients with small hepatocellular carcinoma. Am J Gastroenterol 1988, 83:1386-1389.
76. Fujiyama S, Izuno K, Gohshi K, Shibata J, Sato T: Clinical usefulness of des-gamma-carboxy prothrombin assay in early diagnosis of
hepatocellular carcinoma. Dig Dis Sci 1991, 36:1787-1792.
77. Izuno K, Fujiyama S, Yamasaki K, Sato M, Sato T: Early detection of hepatocellular carcinoma associated with cirrhosis by combined assay of des-gamma-carboxy prothrombin and alpha-fetoprotein: a prospective study. Hepatogastroenterology 1995, 42:387-393.
78. Kuromatsu R, Tanaka M, Shimauchi Y, Shimada M, Tanikawa K, Watanabe K, Yokoo T: Usefulness of ED036 kit for measuring serum PIVKA-II levels in small hepatocellular carcinoma. J Gastroenterol 1997, 32:507-512.
79. Okuda H, Nakanishi T, Takatsu K, Saito A, Hayashi N, Watanabe K, Magario N, Yokoo T, Naraki T: Measurement of serum levels of des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma by a revised enzyme immunoassay kit with increased sensitivity. Cancer 1999, 85:812-818.
80. Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, Fontana RJ, Lok AS:
Des-gamma carboxyprothrombin can differentiate hepatocellular
carcinoma from nonmalignant chronic liver disease in american patients.
Hepatology 2003, 37:1114-1121.
81. Wang CS, Lin CL, Lee HC, Chen KY, Chiang MF, Chen HS, Lin TJ, Liao LY:
Usefulness of serum des-gamma-carboxy prothrombin in detection of hepatocellular carcinoma. World J Gastroenterol 2005, 11:6115-6119.
82. Tanaka Y, Kashiwagi T, Tsutsumi H, Nagasawa M, Toyama T, Ozaki S, Naito M, Ishibashi K, Azuma M: Sensitive measurement of serum abnormal prothrombin (PIVKA-II) as a marker of hepatocellular carcinoma.
Hepatogastroenterology 1999, 46:2464-2468.
83. Ando E, Tanaka M, Yamashita F, Kuromatsu R, Takada A, Fukumori K, Yano Y, Sumie S, Okuda K, Kumashiro R, Sata M: Diagnostic clues for recurrent hepatocellular carcinoma: comparison of tumour markers and imaging studies. Eur J Gastroenterol Hepatol 2003, 15:641-648.
84. Tsai SL, Huang GT, Yang PM, Sheu JC, Sung JL, Chen DS: Plasma des-gamma-carboxyprothrombin in the early stage of hepatocellular carcinoma. Hepatology 1990, 11:481-488.
85. Fujiyama S, Izuno K, Yamasaki K, Sato T, Taketa K: Determination of optimum cutoff levels of plasma des-gamma-carboxy prothrombin and serum alpha-fetoprotein for the diagnosis of hepatocellular carcinoma using receiver operating characteristic curves. Tumour Biol 1992, 13:316-323.
86. Takikawa Y, Suzuki K, Yamazaki K, Goto T, Madarame T, Miura Y, Yoshida T, Kashiwabara T, Sato S: Plasma abnormal prothrombin (PIVKA-II): a new and reliable marker for the detection of hepatocellular carcinoma. J
Gastroenterol Hepatol 1992, 7:1-6.
87. Kasahara A, Hayashi N, Fusamoto H, Kawada Y, Imai Y, Yamamoto H, Hayashi E, Ogihara T, Kamada T: Clinical evaluation of plasma
des-gamma-carboxy prothrombin as a marker protein of hepatocellular carcinoma in patients with tumors of various sizes. Dig Dis Sci 1993, 38:2170-2176.
88. Grazi GL, Mazziotti A, Legnani C, Jovine E, Miniero R, Gallucci A, Palareti G, Gozzetti G: The role of tumor markers in the diagnosis of hepatocellular carcinoma, with special reference to the des-gamma-carboxy prothrombin.